Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1-M1-NK Cells in Advanced Gastric or Colorectal Cancer
NCT07031011Phase 1Not yet recruiting
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PD-1-M1-NK Cells in gastric cancer (GC) and colorectal cancer (CRC). Primary endpoints: Dose-limiting Toxicity at 28 days and The Occurrence of Adverse Events at 90 days. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
PD-1-M1-NK Cells
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07031011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07031011.